File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Circulating microRNAs as biomarkers of radiation-induced cardiac toxicity in non-small-cell lung cancer

TitleCirculating microRNAs as biomarkers of radiation-induced cardiac toxicity in non-small-cell lung cancer
Authors
Issue Date28-Mar-2019
PublisherSpringer
Citation
Journal of Cancer Research and Clinical Oncology, 2019, v. 145, p. 1635-1643 How to Cite?
Abstract

Purpose

Radiation-induced cardiac toxicity (RICT) is an increasingly well-appreciated source of morbidity and mortality in patients receiving thoracic radiotherapy (RT). Currently available methods to predict RICT are suboptimal. We investigated circulating microRNAs (c-miRNAs) as potential biomarkers of RICT in patients undergoing definitive RT for non-small-cell lung cancer (NSCLC).

Methods

Data from 63 patients treated on institutional trials were analyzed. Prognostic models of grade 3 or greater (G3 +) RICT based on pre-treatment c-miRNA levels (‘c-miRNA’), mean heart dose (MHD) and pre-existing cardiac disease (PCD) (‘clinical’), and a combination of these (‘c-miRNA + clinical’) were developed. Elastic net Cox regression and full cross validation were used for variable selection, model building, and model evaluation. Concordance statistic (c-index) and integrated Brier score (IBS) were used to evaluate model performance.

Results

MHD, PCD, and serum levels of 14 c-miRNA species were identified as jointly prognostic for G3 + RICT. The ‘c-miRNA and ‘clinical’ models yielded similar cross-validated c-indices (0.70 and 0.72, respectively) and IBSs (0.26 and 0.28, respectively). However, prognostication was not improved by combining c-miRNA and clinical factors (c-index 0.70, IBS 0.28). The ‘c-miRNA’ and ‘clinical’ models were able to significantly stratify patients into high- and low-risk groups of developing G3 + RICT. Chi-square testing demonstrated a marginally significantly higher prevalence of PCD in patients with high- compared to low-risk c-miRNA profile (p = 0.09), suggesting an association between some c-miRNAs and PCD.

Conclusions

We identified a pre-treatment c-miRNA signature prognostic for G3 + RICT. With further development, pre- and mid-treatment c-miRNA profiling could contribute to patient-specific dose selection and treatment adaptation.


Persistent Identifierhttp://hdl.handle.net/10722/344080
ISSN
2023 Impact Factor: 2.7
2023 SCImago Journal Rankings: 1.023

 

DC FieldValueLanguage
dc.contributor.authorHawkins, Peter G-
dc.contributor.authorSun, Yilun-
dc.contributor.authorDess, Robert T-
dc.contributor.authorJackson, William C-
dc.contributor.authorSun, Grace-
dc.contributor.authorBi, Nan-
dc.contributor.authorTewari, Muneesh-
dc.contributor.authorHayman, James A-
dc.contributor.authorKalemkerian, Gregory P-
dc.contributor.authorGadgeel, Shirish M-
dc.contributor.authorLawrence, Theodore S-
dc.contributor.authorHaken, Randall K Ten-
dc.contributor.authorMatuszak, Martha M-
dc.contributor.authorKong, Feng-Ming-
dc.contributor.authorSchipper, Matthew J-
dc.contributor.authorJolly, Shruti-
dc.date.accessioned2024-06-27T09:07:01Z-
dc.date.available2024-06-27T09:07:01Z-
dc.date.issued2019-03-28-
dc.identifier.citationJournal of Cancer Research and Clinical Oncology, 2019, v. 145, p. 1635-1643-
dc.identifier.issn0171-5216-
dc.identifier.urihttp://hdl.handle.net/10722/344080-
dc.description.abstract<h3>Purpose</h3><p>Radiation-induced cardiac toxicity (RICT) is an increasingly well-appreciated source of morbidity and mortality in patients receiving thoracic radiotherapy (RT). Currently available methods to predict RICT are suboptimal. We investigated circulating microRNAs (c-miRNAs) as potential biomarkers of RICT in patients undergoing definitive RT for non-small-cell lung cancer (NSCLC).</p><h3>Methods</h3><p>Data from 63 patients treated on institutional trials were analyzed. Prognostic models of grade 3 or greater (G3 +) RICT based on pre-treatment c-miRNA levels (‘c-miRNA’), mean heart dose (MHD) and pre-existing cardiac disease (PCD) (‘clinical’), and a combination of these (‘c-miRNA + clinical’) were developed. Elastic net Cox regression and full cross validation were used for variable selection, model building, and model evaluation. Concordance statistic (c-index) and integrated Brier score (IBS) were used to evaluate model performance.</p><h3>Results</h3><p>MHD, PCD, and serum levels of 14 c-miRNA species were identified as jointly prognostic for G3 + RICT. The ‘c-miRNA and ‘clinical’ models yielded similar cross-validated c-indices (0.70 and 0.72, respectively) and IBSs (0.26 and 0.28, respectively). However, prognostication was not improved by combining c-miRNA and clinical factors (c-index 0.70, IBS 0.28). The ‘c-miRNA’ and ‘clinical’ models were able to significantly stratify patients into high- and low-risk groups of developing G3 + RICT. Chi-square testing demonstrated a marginally significantly higher prevalence of PCD in patients with high- compared to low-risk c-miRNA profile (<em>p</em> = 0.09), suggesting an association between some c-miRNAs and PCD.</p><h3>Conclusions</h3><p>We identified a pre-treatment c-miRNA signature prognostic for G3 + RICT. With further development, pre- and mid-treatment c-miRNA profiling could contribute to patient-specific dose selection and treatment adaptation.</p>-
dc.languageeng-
dc.publisherSpringer-
dc.relation.ispartofJournal of Cancer Research and Clinical Oncology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleCirculating microRNAs as biomarkers of radiation-induced cardiac toxicity in non-small-cell lung cancer-
dc.typeArticle-
dc.identifier.doi10.1007/s00432-019-02903-5-
dc.identifier.volume145-
dc.identifier.spage1635-
dc.identifier.epage1643-
dc.identifier.eissn1432-1335-
dc.identifier.issnl0171-5216-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats